A new breakthrough treatment for pancreatic cancer is giving patients like Vicky Stinson, 65, a second chance at life. Diagnosed with Stage III pancreatic cancer in 2024, Stinson was told she had only months to live, but two years on, she’s defying the odds.
Stinson, a retired landscape architect from Flagstaff, Arizona, has been benefiting from a new drug called daraxonrasib, which targets and kills cancer cells with a common mutation. This treatment is part of a new wave of promising therapies, including individualized mRNA vaccines and devices that deliver alternating electrical fields to the abdomen.
Pancreatic Cancer Breakthroughs
About 70,000 Americans are diagnosed with pancreatic cancer each year, with around 80% of cases detected at a late stage. The five-year survival rate for pancreatic cancer remains low, at just 13%, according to the American Cancer Society. However, with new treatments on the horizon, researchers are hopeful that this could change.
Surgical oncologist Rajesh Ramanathan explains that the pancreas is a notoriously difficult organ to treat, due to its location and the vague symptoms of pancreatic cancer. However, new treatments like daraxonrasib are showing promising results, with clinical trial data published in The New England Journal of Medicine showing the drug outperforming chemotherapy.
A New Era for Cancer Treatment
The development of new treatments for pancreatic cancer is part of a broader shift in cancer research, with advances in genetics, immunotherapies, and imaging leading to increased survival rates for other types of cancer. As researchers continue to make breakthroughs, patients like Stinson are holding onto hope that science will help them outrun their cancer.
The impact of these new treatments could be significant, with the potential to transform the way pancreatic cancer is treated and increase survival rates. As the medical community continues to make progress, patients and families affected by pancreatic cancer are looking to the future with renewed optimism.
